EUCTR2018-000108-41-IT进行中（未招募）1 期
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Men and women of age >=18 years
- •2) Eastern Cooperative Oncology Group (ECOG) Performance Status of <=2
- •3) Histologically confirmed malignancy with relapsed/refractory disease:
- •a) After >=2 lines of standard systemic therapy including prior BTK inhibitor therapy:
- •b) After >=2 lines of standard systemic therapy:
- •i) DLBCL-ABC
- •4) For subjects in:
- •a) Phase 1b and 2:
- •Availability of a peripheral blood sample or a bone marrow aspirate or a lymph node biopsy obtained during the screening period for evaluation of predictive/prognostic disease parameters and to determine if there is a functional BTK C481 mutation (ie BTK C481S) or a resistance or gain of function mutation(s) (ie, PLC¿2 R665W)
- •b) Phase 2 only:
- •i) For CLL: the presence of a functional BTK C481 mutation (ie, >=1% BTK C481 mutation), and absence of a resistance or gain of function mutation (ie, PLC¿2 R665W) or
- •ii) For CLL: absence of a functional BTK C481mutation alone (<1% BTK C481 mutation)
- •iii) For LPL/WM: no mutation requirement
- •iv) For MCL: no mutation requirement
- •5) Presence of measurable disease:
- •a) For subjects with SLL, MCL, DLBCL-ABC, FL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy
- •b) For subjects with LPL/WM: presence of serum monoclonal immunoglobulin protein (M-protein) >=1 g/dL (but subject does not have symptomatic hyperviscosity syndrome [HVS] and does not require immediate plasmapheresis for control of HVS)
- •6) Current medical need for therapy of the B-lymphoid malignancy due to disease-related symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or PD
- •7) An interval of >=3 half-lives (unless the last therapy was an antibody where 1 half-life or 14 days, whichever is shorter, is acceptable with demonstrated progression by standard guidelines) from the completion of all previous antitumor therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) to the start of study therapy
- •8) All acute toxic effects of any prior antitumor therapy resolved to Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], neurotoxicity [Grade <=2 permitted], or selected laboratory parameters [Grade <=2 permitted with exceptions noted below])
- •9) Adequate thyroid function (TSH, T3, T4) with or without thyroid replacement (Grade <=2)
- •10) Adequate hepatic profile:
- •a) Serum alanine aminotransferase (ALT) <=3 × upper limit of normal (ULN) (Grade <=1)
- •b) Serum aspartate aminotransferase (AST) <=3 × ULN (Grade< =1)
- •c) Serum alkaline phosphatase (ALP) <=2.5 × ULN (Grade <=1)
- •d) Serum bilirubin =1.5 × ULN (Grade <=1) except for subjects with Gilbert’s disease
- •11) Adequate renal function:
- •a) Estimated creatinine clearance (eClCR) >45 mL/minute (with eClCR to be calculated by the Cockcroft-Gault formula),
- •b) Measured creatinine clearance >45 mL/minute (assessed with a 24 hour urine collection)
- •12) Adequate pancreatic profile:
- •a) Serum amylase <=1.5 × ULN (Grade <=1)
- •b) Serum lipase <=1.5 × ULN (Grade <=1)
- •13) Hematology Requirements:
- •a) Platelet count >=50 × 109/L (Grade <=2) maintained for >=7 days after any prior transfusion
- •b) For subjects without bone marrow involvement:
- •i) Absolute neutrophil count (ANC) >=0.750 × 109/L
- •ii) Hemoglobin (Hb) >=8.0 g/dL, stable for >=7 days
- •c) For subjects with bone marrow involvement:
- •i) Absolute neutrophil count (ANC) >=500 cells/µL
- •14) Adequate coagulation profile:
排除标准
- •1) Transformed disease at time of screening (eg, Richter’s transformation or of blastoid variant MCL)
- •2) Known central nervous system malignancy
- •Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.
- •3) History of another malignancy except for the following adequately treated:
- •a) Local basal cell or squamous cell carcinoma of the skin
- •b) Carcinoma in situ of the cervix or breast
- •c) Papillary, noninvasive bladder cancer
- •d) Prostate cancer Stage 1 and 2 for which observation is clinically indicated with stable prostate-specific antigen (PSA) for 6 months
- •e) Other Stage 1 or 2 cancers currently in complete remission
- •f) Any other cancer that has been in complete remission for 2 years or surgically cured
- •4) Significant cardiovascular disease
- •a) Myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism within 6 months prior to start of study therapy
- •b) Symptomatic angina
- •c) Symptomatic peripheral vascular disease
- •d) New York Heart Association Class >=3 congestive heart failure
- •e) Uncontrolled Grade >=3 hypertension (diastolic blood pressure >=100 mmHg or systolic blood pressure >=160 mmHg) despite antihypertensive therapy
- •f) Uncontrolled arrhythmia
- •5) Significant screening ECG abnormalities:
- •a) Left bundle branch block
- •b) 2nd or 3rd-degree Atrioventricular block Type 2
- •c) Grade >=2 bradycardia
- •d) QTc by either Bazett or Fridericia method (QTcB or QTcF) >450 msec (for men) or >470 msec (for women)
- •6) Gastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs
- •7) Ongoing risk for bleeding due to any of the following:
- •a) Bleeding diathesis
- •b) Known platelet function disorder
- •c) Uncontrolled peptic ulcer disease
- •d) Oral anticoagulation (eg, warfarin, apixaban, rivaroxaban, dabigatran etexilate)
- •e) Heparin, low-molecular-weight heparin or heparin fractions (eg, enoxaparin, dalteparin, fondaparinux)
- •Note: Use of heparin or thrombolytic agents for local maintenance or clearance of a central venous catheter is permitted.
- •8) Evidence of an uncontrolled systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy
- •Note: Subjects with localized fungal infections of skin or nails are eligible.
- •9) Demonstrated intolerance to a BTK inhibitor as evidenced by discontinuation of BTK inhibitor due to AE or required dose reduction due to AE
- •10) Transplant
- •a) Evidence of ongoing graft-versus-host disease after prior stem cell transplant
- •b) Prior solid organ transplant
- •11) Pregnancy or breastfeeding
- •12) Major surgery within 4 weeks before the start of study therapy
- •13) Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids except as noted
- •Note: At screening, subjects may be using systemic corticosteroids (at physiologic doses of <=10 mg/day of prednisone or equivalent) or topical or inhaled corticosteroids.
- •14) Use of a moderate or strong inhibitor or inducer of CYP3A4 within 7 days prior to the start of study therapy or expected requirement for use during study therapy
- •15) Use of substrates of CYP2C8, CYP3A4, CYP2B6, CYP2C9 and CYP2D6 with narrow therapeutic index within 7 days prior to the start of study therapy or expected requireme
研究者
相似试验
进行中（未招募）
1 期
A study to determine the safety profile and recommended dose of SNS-062 for further evaluation of a new cancer agent to treatment relapsed or resistant B-lymphoid cancers.Male or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequent BTK inhibition using SNS-062.MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.1Level: HLTClassification code 10047802Term: Waldenstrom's macroglobulinaemiasSystem Organ Class: 100000004851MedDRA version: 21.0Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2018-000108-41-ESSunesis Pharmaceuticals, Inc.174
进行中（未招募）
1 期
A study to determine the safety profile and recommended dose of SNS-062 for further evaluation of a new cancer agent to treatment relapsed or resistant B-lymphoid cancersMale or female adult patients with an advanced B-Lymphoid malignancies that have relapsed/progressed after appropriate prior therapy and have resistance and/or mutations that may respond to subsequent BTK inhibition using SNS-062.MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 20.1Level: HLTClassification code 10047802Term: Waldenstrom's macroglobulinaemiasSystem Organ Class: 100000004851MedDRA version: 20.1Level: LLTClassification code 10008948Term: Chronic leukemiaSystem Organ Class: 100000004864EUCTR2018-000108-41-GBSunesis Pharmaceuticals, Inc.124
进行中（未招募）
1 期
A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumumab, and Dexamethasone plus Pomalidomide in Multiple Myelomarelapsed or refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2023-507751-30-00Beigene Ltd.211
进行中（未招募）
1 期
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC or Hepatocellular Carcinoma.Advanced Refractory SolidTumours (Phase 1b) and in Recurrent or RefractoryNon–Small Cell Lung Cancer or Hepatocellular Carcinoma, (Phase 2)EUCTR2015-002093-20-DEEli Lilly and Company75
已完成
1 期
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumorseoplasms by SiteJPRN-jRCT2080223834Bristol-Myers Squibb K.K.1,000